Top brand choice
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
FIRVANQ® is a glycopeptide antibacterial indicated in adults and pediatric patients less than 18 years of age for the treatment of: Clostridium difficile-associated diarrhea. Enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).
Parenteral administration of vancomycin is not effective for the above infections; therefore, vancomycin must be given orally for these infections. Orally administered vancomycin hydrochloride is not effective for treatment of other types of infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FIRVANQ® and other antibacterial drugs, FIRVANQ® should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. Contraindications: FIRVANQ® is contraindicated in patients with known hypersensitivity to vancomycin.
The most common adverse reactions (= 10%) were nausea (17%), abdominal pain (15%), and hypokalemia (13%).